alexa Pulmonary valve stenosis | Australia | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • International Conference on Internal Medicine
    May 21-22, 2018 Osaka, Japan
  • 3rd International Conference on Anesthesia
    June 21-22, 2018 Dublin, Ireland
  • Annual Congress on Research and Innovations in Medicine
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Emergency & Acute Care Medicine
    August 22-23, 2018 Tokyo, Japan

Pulmonary Valve Stenosis

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Pulmonary valve stenosis

    Pulmonary valve stenosis is a condition characterized by obstruction to blood flow from the right ventricle to the pulmonary artery. This obstruction is caused by narrowing (stenosis) at one or more points from the right ventricle to the pulmonary artery. The most common form of pulmonary stenosis is obstruction at the valve itself, referred to as pulmonary valvar stenosis.

  • Pulmonary valve stenosis

    Pulmonary valve stenosis signs and symptoms vary, depending on the extent of the obstruction. People with mild pulmonary stenosis usually don't have symptoms. Pulmonary valve stenosis signs and symptoms may include Heart murmur - an abnormal whooshing sound heard using a stethoscope, caused by turbulent blood flow, Shortness of breath, especially during exertion, Chest pain, Loss of consciousness (fainting), Fatigue.

  • Pulmonary valve stenosis

    In Australia statistical analysis on pulmonary valve stenosis given result as fourteen studies were quantitatively assessed and included for meta-analysis, including two randomized controlled trials and eleven observational studies. Results indicated no significant differences between TAVI and AVR in terms of all-cause and cardiovascular related mortality, stroke, myocardial infarction or acute renal failure. A subgroup analysis of randomized controlled trials identified a higher combined incidence of stroke or transient ischemic attacks in the TAVI group compared to the AVR group. TAVI was also found to be associated with a significantly higher incidence of vascular complications, permanent pacemaker requirement and moderate or severe aortic regurgitation.

Expert PPTs

Speaker PPTs


High Impact List of Articles

Conference Proceedings